Oncotarget

Dr. Blagosklonny, an expert in NSCLC treatment, discusses overcoming resistance in lung cancer therapy. He delves into the challenges with current EGFR inhibitors, the potential of Osimertinib as a third-generation TKI, and the use of preemptive combinations to enhance treatment outcomes.

Researchers explore synergistic cytotoxicity in pancreatic cancer cells by combining HDAC and PARP inhibitors with Decitabine, offering potential for novel therapeutic approaches. The study delves into the impact of specific drug combinations on pancreatic cancer cell lines, highlighting promising results for personalized treatment strategies.

Researchers from Atrium Health discuss the cardiotoxicity of BTK inhibitors, focusing on predictive biomarkers and risk stratification. Genetic markers like KCNQ1 and GATA4 show promise in identifying high-risk patients, emphasizing the need for a clinicogenomic risk model for improved patient management.

Dr. Benoit Chabot discusses the anticancer potential of CLK kinase inhibitors 1C8 and GPS167, impacting cell proliferation and gene expression. The compounds influence pathways like MIC targets, TGF beta signaling, and splicing mechanisms, potentially affecting metastasis and antiviral immune response.

Researchers from Perderzoli Hospital discuss the importance of integrated therapies on cancer, focusing on Silibinin's anti-inflammatory properties as a potential adjuvant to standard cancer treatments for reducing toxicity and improving outcomes.

Delving into the challenges of AML treatment and the search for innovative solutions to combat relapse through a new study targeting drug resistance. Exploring GHRH antagonists in treating AML and inhibiting drug-resistant leukemia cells. Investigating the efficacy of MIA-602 in combating Doxorubicin-resistant AML with promising antiproliferative effects. Discussing novel therapeutic strategies for overcoming drug resistance in AML and the importance of translating preclinical discoveries into personalized clinical treatments.

Researchers Laurence Booth, Jane L. Roberts, and others discuss GZ17-6.02's efficacy in killing uveal melanoma cells. They cover the compound's components, safety evaluations, phase I trials, interactions with inhibitors, and its impact on cell signals for tumor cell elimination.

Researchers discuss the anticancer potential of CLK kinase inhibitors 1C8 and GPS167, revealing their impact on cancer cell proliferation, epithelial-mesenchymal transition, and antiviral immune response. Molecular mechanisms underlying the inhibitors' effects on processes critical for metastasis are explored.

Researchers Wesliany Everton Duarte, Jaqueline Diniz Pinho, Syomara Pereira da Costa Melo, and others discuss their study on Cyclin D1 expression in penile cancer patients, revealing significant correlations with clinical and histopathological features. The study surveyed 100 patients and highlighted the importance of further research in understanding the role of Cyclin D1 in penile cancer.

The podcast discusses Impact Journals' focus on cancer and aging research, highlighting Oncotarget as a leading journal in the field. It explores the efforts to connect different disciplines in oncology and biomedical sciences for better research outcomes.